consensu expect million adjust ep versu
consensu expect view surpris given
sign strong quarter overal joint replac market
syk result quarter achiev organ growth
led improv perform knee organ closer
exclud rosa knee system sale hip organ
well continu robust growth overal asia pacif segment
organ favor top-lin result higher-than-anticip
incom also enabl increas invest area sale forc
expans surgeon train medic educ still approach
upper end adjust ep guidanc
expect adjust ep versu prior consensu
expect adjust oper margin versu
prior commit level expans level
zbh organ growth guidanc slightli better
rang would expect extra sale day year-over-
year account differ
biggest posit surpris zbh earn call
announc new restructur program compani expect
help propel adjust oper margin least
repres meaning chang recent perform zbh adjust
oper margin contract past four year total
expect annual cost save million end
restructur program million one-tim cost half
expect occur contribut compani expect
oper cash flow declin billion
earn call manag mention recent fda re-
inspect biomet warsaw manufactur facil result eight
fda observ compani call manag
total debt total asset
achiev modest upsid consensu expect led
appear strong quarter joint replac market continu
robust growth asia pacif busi compani also provid
remain ahead achiev object invest busi
acceler revenu growth rais adjust ep estim
primarili reflect slightli better organ growth rate
import pleas read disclosur disclaim page report
report adjust ep consensu expect estim
quarter compani adjust oper incom slightli forecast higher incom
account upsid rel adjust ep estim
zbh revenu increas year-over-year million consensu expect
million million estim quarter zbh organ growth exceed
forecast currenc chang reduc compani revenu growth year-over-year
adjust incom statement analysisnorthcoast research million except percent per share sg interest expens interest expens incom incom incom incom margin com share compani report northcoast research estim factset
product categori standpoint better-than-anticip perform zbh hip knee segment well
overal asia pacif busi organ despit tough comparison help off-set
weaker-than-expect result product note zbh strong joint replac growth
surpris investor follow similar upsid versu expect syk hip
knee implant busi quarter contrast compani attribut slower growth product
time issu particularli impact capit item surgic segment
knee post organ growth estim quarter knee
implant market growth appear strong zbh result also benefit initi roll-out rosa
total knee applic contribut slightli half compani knee organ growth
given roughli million increment knee product sale constant currenc standpoint approxim
increment knee product sale rosa averag sell price rosa knee million
rang estim sold roughli rosa total knee applic unit closer rosa total
inc organ growth analysi reflect pro forma result zimmer biomet compani report northcoast organ growth analysisnorthcoast currenc constant currenc acquisit divestitur organ hip knee spine cmf dental compani report northcoast research estim knee unit year similar zbh knee organ growth favor across geographi robust
asia pacif result organ healthi perform emea organ america
organ driven primarili rosa
hip post posit organ growth exceed forecast compar
market rate similar knee zbh hip busi led except perform asia pacif
organ rel stabl result america notabl see hip busi one grow
around market rate recent new product launch includ avenir complet upcom
roll-out rosa hip applic provid potenti catalyst out-performance
zbh adjust oper margin declin bp year-over-year
forecast quarter compani adjust gross margin exceed forecast bp year-over-year
aid time issu adjust sg expens higher anticip increas
inc knee organ growth analysi reflect pro forma result zimmer biometsourc compani report northcoast inc hip organ growth analysi reflect pro forma result zimmer biometsourc compani report northcoast invest area sale forc expans surgeon train medic educ effort help
acceler futur revenu growth notabl zbh price growth improv slightli year-over-
year versu year-over-year larg reflect one-tim event hurt product price
expect adjust ep versu prior consensu expect adjust
oper margin versu prior commit level expans level
zbh organ growth guidanc slightli better rang
would expect extra sale day year-over-year account differ notabl
follow-up call zbh investor relat depart heard compani expect
light china revenu result coronaviru earli say impact
confid note zbh china busi account less revenu
biggest posit surpris zbh earn call announc new restructur program
compani expect help propel adjust oper margin least
repres meaning chang recent perform zbh adjust oper margin contract
past four year total expect annual cost save million end
restructur program million one-tim cost half expect occur
contribut compani expect oper cash flow declin billion
earn call manag mention recent fda re-inspect biomet warsaw
manufactur facil result eight fda observ compani call manag
remedi work remain note previous suggest product suppli facil
barrier achiev financi commit least last year
overal achiev modest upsid consensu expect led appear strong
quarter joint replac market continu robust growth asia pacif busi compani
also provid encourag adjust oper margin target although signific work remain ahead
achiev object invest busi acceler revenu growth rais
adjust ep estim primarili reflect slightli better organ growth rate
inc annual incom statement analysi adjust northcoast research million except percentag per share gross gross sg sg oper oper net interest incom net interest incom incom incom incom tax minor incom extra incom extra extra net net wghd com share ep ep growth ep growth compani report northcoast research estim disclosur
